Samsung Bioepis, Teva Expand Biosimilar Partnership
Samsung Bioepis and Teva have expanded their strategic partnership to advance up to six potential biosimilar candidates.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Samsung Bioepis, Teva Expand Biosimilar Partnership to Six Candidates
Samsung Bioepis and Teva Pharmaceutical Industries have expanded their global license, development, and commercialization agreement to include up to six potential biosimilar candidates, two of which are confirmed investigational biosimilars.